Skip to main content

This website is intended for use by US residents only.

Prescribed CRYSVITA for XLH? Kyowa Kirin Cares can support your treatment journey

Kyowa Kirin Cares is a program with dedicated specialists, Case Managers, and Clinical Educators who can connect patients and caregivers to the support they need—from access and reimbursement assistance to ongoing support during treatment.

A woman smiling at her desk with a headset on

Talk to your doctor about enrolling in Kyowa Kirin Cares

Before enrolling

For you or your child to be prescribed CRYSVITA, your doctor may need to provide the insurance company with information such as:

  • Medical records confirming an XLH diagnosis, which may include genetic or other testing
  • Family history of XLH
  • Medical history of symptoms and treatment

After enrolling

A person with a headset on

A Case Manager will help you NAVIGATE treatment:

  • Assist you with logistical information regarding access, reimbursement, and financial options
  • Explain how to work with your specialty pharmacy
  • Work with your healthcare team to ensure that you get your CRYSVITA injections as prescribed
  • Support you over time to help you stay on track with treatment
A person with a book

A Clinical Educator will help to EDUCATE you about disease and treatment:

  • Learn more about XLH
  • Understand your treatment with CRYSVITA and what to expect
  • Provide tips, tools, and resources to help you stay on track
  • Connect with you along your treatment journey

For more information, call 833-KK-CARES (833-552-2737) Monday through Friday, 8AM to 8PM (ET), or visit Kyowa Kirin Cares.

Steps for enrollment in Kyowa Kirin Cares

Step 1: Complete enrollment form

Your doctor will need to fill out the Kyowa Kirin Cares CRYSVITA enrollment form with your or your child’s basic information, insurance information, and the doctor’s prescription information. Your doctor can download this form from the website.

Download the Enrollment Form (PDF) file download icon

Step 2: Benefits investigation

After receiving the completed enrollment form, Kyowa Kirin Cares will begin your or your child’s benefits investigation (BI) process.

Step 3: Confirmation of benefits status

Once completed, your or your child’s doctor will be informed of the status of the BI. If CRYSVITA is covered by insurance, the Case Manager will review your or your child’s benefits with the doctor. If a prior authorization or exception is required, a Case Manager will contact your or your child’s doctor to inform them of the next steps needed.

If you have commercial insurance, once enrolled in the Kyowa Kirin Cares program, you can speak with your or your child’s Case Manager about enrolling in the Kyowa Kirin Cares Co-Pay Assistance Program.

$0

Kyowa Kirin Cares Co-Pay Assistance Program

$0 out-of-pocket cost

95% of the eligible, commercially insured patients who were enrolled in the Kyowa Kirin Cares
Co-Pay Assistance Program had $0 out-of-pocket costs for CRYSVITA.*

The information provided on this page is intended for informational purposes, and should not be considered a guarantee of treatment or coverage. Restrictions apply. For additional information about eligibility, please see the below Program Terms and Conditions.

Patients who are enrolled in any federal or state healthcare program, including, without limitation, Medicaid, Managed Medicaid, Medicare, Medicare Advantage, Medigap, CHAMPVA, TriCare, Veterans Affairs (VA), or Department of Defense (DoD), or any state or patient assistance program are not eligible for Kyowa Kirin Cares Co-Pay Assistance Program. The Kyowa Kirin Cares Co-Pay Assistance Program for CRYSVITA helps commercially insured individuals who are residents of the United States (including the United States territories) and who are prescribed CRYSVITA for a use approved by the Food and Drug Administration (FDA) pay for their eligible out-of-pocket costs and cost-sharing for CRYSVITA and the associated cost-sharing for drug administration, up to a specified maximum benefit per calendar year. To learn the maximum benefit of financial assistance available to you under the Kyowa Kirin Cares Co-Pay Assistance Program, call Kyowa Kirin Cares at 833-KK-CARES (833-552-2737). Either the patient, or the patient’s legal guardian or representative, must personally enroll in the Kyowa Kirin Cares Co-Pay Assistance Program. Health insurance plans, pharmacy benefit managers, employers, payors, or any of their representatives or agents are prohibited from enrolling patients or assisting patients with enrolling in the Kyowa Kirin Cares Co-Pay Assistance Program.

Note that individuals residing in Massachusetts or Rhode Island (or elsewhere as prohibited by law) may not be eligible for financial assistance related to the administration/injection of CRYSVITA. In order to be eligible for the Program, individuals must provide a signed authorization compliant with the Health Insurance Portability and Accountability Act of 1996 and the regulations thereunder (collectively “HIPAA”). The Program does not cover the costs of physician office visits or evaluations, blood work or other testing, or transportation or other related services. Individuals may not seek reimbursement from any health savings, flexible savings, or other healthcare reimbursement account for any amounts received from the Co-Pay Assistance Program. Claims accrued 90 days prior to enrollment in Kyowa Kirin Cares will not be eligible for Co-Pay Assistance. The Program is NOT insurance. Void if copied, transferred, purchased, altered, or traded, and where prohibited and restricted by law. For additional terms and conditions, call Kyowa Kirin Cares at 833-KK-CARES (833-552-2737).

The above set of Terms and Conditions are subject to change at any time without prior notification. Kyowa Kirin reserves the right to make eligibility determinations, to set parameters for its Programs, to monitor participation, and to change, modify, or discontinue its Programs at any time without notice.

Starting CRYSVITA? Learn more about setting up shipments and appointments

Receiving your prescription
Medicine

Not actual size

Two speech bubbles

Additional Kyowa Kirin Cares financial assistance options

Other financial assistance for CRYSVITA may be available to patients who qualify. Once you are prescribed CRYSVITA, you can ask a Kyowa Kirin Cares Case Manager for more information.

Call 833-KK-CARES (833-552-2737) Monday through Friday, 8 AM to 8 PM (ET), to speak with a Kyowa Kirin Cares Case Manager about financial assistance options.

This information doesn’t replace talking with your doctor. Be sure to ask them about CRYSVITA and whether it’s right for you.

Real XLH stories

Finding better days ahead

“Try to keep positive. If you’re feeling down, talk to somebody who understands what you’re going through.”

Robert, a person living with XLH, smiling

Robert, currently on CRYSVITA

A smartphone with the Find an XLH Specialist page on the screen

Need help finding a doctor who manages XLH?

Indication
What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 6 months of age and older with X-linked hypophosphatemia (XLH).


What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 6 months of age and older with X-linked hypophosphatemia (XLH).

Important Safety Information

You should not take CRYSVITA if:

  • You take an oral phosphate supplement and/or a specific form of vitamin D supplement (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
  • Your phosphorus levels from a blood sample are within or above the normal range for age.
  • You have kidney problems.

What is the most important information you should know about CRYSVITA?

  • Some patients developed allergic reactions (e.g., rash and hives) while taking CRYSVITA. Your doctor will monitor you for symptoms of an allergic reaction while you are taking CRYSVITA. Your treatment may need to be discontinued for serious allergic reactions.
  • High levels of phosphorus in the blood have been reported in some patients taking CRYSVITA. This may be related to a risk of high calcium levels in the kidneys. Your doctor will collect blood samples to monitor your levels. If you are already taking CRYSVITA, dose interruption and/or dose reduction may be required based on your serum phosphorus levels.
  • High levels of calcium in the blood have been reported in patients taking CRYSVITA. The risk is greater in patients with pre-existing hyperparathyroidism (overactive parathyroid glands), for those who are unable to move for extended periods of time, become dehydrated, have high vitamin D levels, or have kidney issues. If you are at greater risk, your doctor will monitor your blood calcium and parathyroid hormone levels before you start and while taking CRYSVITA. If you develop high levels of blood calcium, your doctor may need to stop your treatment until it is adequately managed.
  • Administration of CRYSVITA may result in reactions at the injection site, such as hives, reddening of the skin, rash, swelling, bruising, pain, severe itching of the skin, and collection of blood outside of a blood vessel (i.e., hematoma). Call your doctor if you develop an injection site reaction. CRYSVITA may be discontinued if severe injection site reactions occur.

What are the possible side effects of CRYSVITA?

  • Adverse reactions that were seen in children with XLH are:
  • Fever
  • Injection site reaction
  • Cough
  • Vomiting
  • Pain in arms and legs
  • Headache
  • Tooth abscess
  • Dental cavities
  • Diarrhea
  • Decreased vitamin D levels
  • Toothache
  • Constipation
  • Muscle pain
  • Rash
  • Dizziness
  • Nausea
  • Adverse reactions that were seen in adults with XLH are:
  • Back pain
  • Headache
  • Tooth infection
  • Restless legs syndrome
  • Decreased vitamin D levels
  • Dizziness
  • Constipation
  • Muscle spasms
  • Phosphorus levels increased in the blood
  • Narrowing of the spaces within the spine is common in adults with XLH, and pressure on the spinal cord has been reported in adults taking CRYSVITA. It is not known if taking CRYSVITA worsens the narrowing of the spaces within the spine or the pressure on the spinal cord.

Before taking CRYSVITA, tell your doctor about all of your medications (including supplements) and medical conditions, including if you:

  • Are taking oral phosphate and/or active vitamin D (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
  • Are pregnant, think you may be pregnant, or plan to become pregnant. There is not enough experience to know if CRYSVITA may harm your unborn baby. Report pregnancies to the Kyowa Kirin, Inc. Adverse Event reporting line at 1-844-768-3544.
  • Are breastfeeding or plan to breastfeed. There is not enough experience to know if CRYSVITA passes into your breast milk. Talk with your doctor about the best way to feed your baby while you receive CRYSVITA.

While taking CRYSVITA, tell your doctor if you experience:

  • An allergic reaction such as rash or hives
  • A rash, swelling, bruising, or other reaction at the injection site
  • New or worsening restless legs syndrome

These are not all the possible side effects of CRYSVITA. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Kyowa Kirin, Inc. at 1-844-768-3544.

For important risk and use information, please see the full Prescribing Information for CRYSVITA.

What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 6 months of age and older with X-linked hypophosphatemia (XLH).

Important Safety Information

You should not take CRYSVITA if:

  • You take an oral phosphate supplement and/or a specific form of vitamin D supplement (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
  • Your phosphorus levels from a blood sample are within or above the normal range for age.
  • You have kidney problems.

What is the most important information you should know about CRYSVITA?

  • Some patients developed allergic reactions (e.g., rash and hives) while taking CRYSVITA. Your doctor will monitor you for symptoms of an allergic reaction while you are taking CRYSVITA. Your treatment may need to be discontinued for serious allergic reactions.
  • High levels of phosphorus in the blood have been reported in some patients taking CRYSVITA. This may be related to a risk of high calcium levels in the kidneys. Your doctor will collect blood samples to monitor your levels. If you are already taking CRYSVITA, dose interruption and/or dose reduction may be required based on your serum phosphorus levels.
  • High levels of calcium in the blood have been reported in patients taking CRYSVITA. The risk is greater in patients with pre-existing hyperparathyroidism (overactive parathyroid glands), for those who are unable to move for extended periods of time, become dehydrated, have high vitamin D levels, or have kidney issues. If you are at greater risk, your doctor will monitor your blood calcium and parathyroid hormone levels before you start and while taking CRYSVITA. If you develop high levels of blood calcium, your doctor may need to stop your treatment until it is adequately managed.
  • Administration of CRYSVITA may result in reactions at the injection site, such as hives, reddening of the skin, rash, swelling, bruising, pain, severe itching of the skin, and collection of blood outside of a blood vessel (i.e., hematoma). Call your doctor if you develop an injection site reaction. CRYSVITA may be discontinued if severe injection site reactions occur.

What are the possible side effects of CRYSVITA?

  • Adverse reactions that were seen in children with XLH are:
  • Fever
  • Injection site reaction
  • Cough
  • Vomiting
  • Pain in arms and legs
  • Headache
  • Tooth abscess
  • Dental cavities
  • Diarrhea
  • Decreased vitamin D levels
  • Toothache
  • Constipation
  • Muscle pain
  • Rash
  • Dizziness
  • Nausea
  • Adverse reactions that were seen in adults with XLH are:
  • Back pain
  • Headache
  • Tooth infection
  • Restless legs syndrome
  • Decreased vitamin D levels
  • Dizziness
  • Constipation
  • Muscle spasms
  • Phosphorus levels increased in the blood
  • Narrowing of the spaces within the spine is common in adults with XLH, and pressure on the spinal cord has been reported in adults taking CRYSVITA. It is not known if taking CRYSVITA worsens the narrowing of the spaces within the spine or the pressure on the spinal cord.

Before taking CRYSVITA, tell your doctor about all of your medications (including supplements) and medical conditions, including if you:

  • Are taking oral phosphate and/or active vitamin D (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
  • Are pregnant, think you may be pregnant, or plan to become pregnant. There is not enough experience to know if CRYSVITA may harm your unborn baby. Report pregnancies to the Kyowa Kirin, Inc. Adverse Event reporting line at 1-844-768-3544.
  • Are breastfeeding or plan to breastfeed. There is not enough experience to know if CRYSVITA passes into your breast milk. Talk with your doctor about the best way to feed your baby while you receive CRYSVITA.

While taking CRYSVITA, tell your doctor if you experience:

  • An allergic reaction such as rash or hives
  • A rash, swelling, bruising, or other reaction at the injection site
  • New or worsening restless legs syndrome

These are not all the possible side effects of CRYSVITA. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Kyowa Kirin, Inc. at 1-844-768-3544.

For important risk and use information, please see the full Prescribing Information for CRYSVITA.

Go to top button

Back to top

COMM-US-CRY-0929 June 2026